Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
Renaissance genius Leonardo da Vinci’s litany of exquisite but unfinished work shows he probably had an attention disorder common to modern society.
For people without heart disease, taking a daily aspirin to prevent heart attacks and strokes may increase the risk of severe brain bleeding to the point where it outweighs any potential benefit, a research review suggests.
Abbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions
Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.
Researchers with the University of California, San Francisco (UCSF) developed a “neural decoder” that translates brain activity to synthesize audible speech, which was published in the journal Nature.
Yale University scientists succeeded in restoring basic cellular activity in pigs’ brains hours after their deaths in a finding that may one day lead to advances in treating human stroke and brain injuries, researchers reported.
A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.
Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.
An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease.
A global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.